Open AccessDevelopment and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections
Author(s) -
Adam J. Plaunt,
Sasha J. Rose,
Jeong Yeon Kang,
KuanJu Chen,
Daniel LaSala,
Ryan P Heckler,
Arielle Dorfman,
Barrett T Smith,
Donald Chun,
Veronica Viramontes,
Antonio Macaluso,
Zhili Li,
Yuchen Zhou,
Lilly Mark,
Jessica Basso,
Franziska Leifer,
Michel R. Corboz,
Richard W. Chapman,
David Cipolla,
Walter R. Perkins,
Vladimir Malinin,
Donna M. Konicek
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00316-21
Subject(s) - vancomycin , methicillin resistant staphylococcus aureus , antibiotics , staphylococcus aureus , in vivo , medicine , pharmacology , pharmacokinetics , microbiology and biotechnology , inhalation , pharmacodynamics , staphylococcal infections , biology , bacteria , anesthesia , genetics
Chronic pulmonary methicillin-resistantStaphylococcus aureus (MRSA) disease in cystic fibrosis (CF) has a high probability of recurrence following treatment with standard-of-care antibiotics and represents an area of unmet need associated with reduced life expectancy. We developed a lipoglycopeptide therapy customized for pulmonary delivery that not only demonstrates potent activity against planktonic MRSA, but also against protected colonies of MRSA both in biofilms and within cells, the latter of which have been linked to clinical antibiotic failure.